Christopher G. Danes, Ph.D.
Affiliations: | 2007 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
OncologyGoogle:
"Christopher Danes"Parents
Sign in to add mentor| Dihua Yu | grad student | 2007 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (14-3-3 zeta overexpression in early stage breast disease and tumor progression.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pradeep S, Huang J, Mora EM, et al. (2015) Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell |
| Merritt WM, Danes CG, Shahzad MM, et al. (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biology & Therapy. 8: 1596-603 |
| Shahzad MM, Lu C, Lee JW, et al. (2009) Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biology & Therapy. 8: 1027-34 |
| Neal CL, Yao J, Yang W, et al. (2009) 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Research. 69: 3425-32 |
| Spannuth WA, Nick AM, Jennings NB, et al. (2009) Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of Cancer. Journal International Du Cancer. 124: 1045-53 |
| Danes CG, Wyszomierski SL, Lu J, et al. (2008) 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Research. 68: 1760-7 |